The DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Alpha‐Synuclein as a Biomarker for Parkinson's Disease
Open accessAbstract
Parkinson's disease (PD) is a common neurodegenerative disorder, characterized pathologically by the presence of α‐synuclein (α‐syn)‐rich Lewy bodies. As clinical diagnosis of PD is challenging, misdiagnosis is common, highlighting the need for disease‐specific and early stage biomarkers. Both early diagnosis of PD and adequate tracking of disease progression could significantly improve outcomes for patients, particularly in regard to existing and future disease modifying treatments. Given its critical roles in PD pathogenesis, α‐syn may be useful as a biomarker of PD. The aim of this review is, therefore, to summarize the efficacy of tissue and body fluid α‐syn measurements in the detection of PD as well as monitoring disease progression. In comparison to solid tissue specimens and biopsies, biofluid α‐syn levels may be the most promising candidates in PD diagnosis and progression based on specificity, sensitivity and availability. Although α‐syn has been tested most extensively in cerebrospinal fluid (CSF), the relatively invasive procedure for collecting CSF is not suitable in most clinical settings, leading to investigation of plasma, blood and saliva as alternatives. The exploration of combined biomarkers, along with α‐syn, to improve diagnostic accuracy is also likely required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although elevated concentrations of α-syn in blood have been proposed as an early biomarker of Parkinson’s disease, identifying brain-derived α-syn is challenging due to its ubiquitous presence in different tissues, such as CSF, blood, saliva, tears, and peripheral tissues [145, 146].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [146]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Parkinson's disease: clinical features and diagnosis
Jankovic, J. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.131045 · Cited by 5,720
Overdependence on degraded gist memory in Alzheimer's disease.
Gallo, D. A., Shahid, K. R., Olson, M. A., Solomon, T. M., Schacter, D. L., & Budson, A. E. (2006) · Neuropsychology · doi:10.1037/0894-4105.20.6.625 · Cited by 4,757
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Clinical diagnostic criteria for dementia associated with Parkinson’s disease
Emre, M., Aarsland, D., Brown, R., Burn, D. J., Duyckaerts, C., Mizuno, Y., Broe, G. A., Cummings, J., Dickson, D. W., Gauthier, S., et al. (2007) · Movement Disorders · doi:10.1002/mds.21507 · Cited by 3,027
α-Synuclein is phosphorylated in synucleinopathy lesions
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., & Iwatsubo, T. (2002) · Nature Cell Biology · doi:10.1038/ncb748 · Cited by 2,174
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 2,072
A systematic review of prevalence studies of dementia in Parkinson's disease
Aarsland, D., ZACCAI, J. H., & Brayne, C. (2005) · Movement Disorders · doi:10.1002/mds.20527 · Cited by 1,714
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–312 of 312
Fei, Y., Hao, M., Liu, J., Dong, Y., Zou, H., Guo, X., An, S., Sang, J., & Xu, T. (2026) · Phytotherapy Research · doi:10.1002/ptr.70392
Ichie, K. E., Asomugha, A. L., & Okafor, I. A. (2026) · BMC Neuroscience · doi:10.1186/s12868-026-01019-0
Xie, H., Zhu, M., Zhu, Z., Tang, J. W., Zhang, R., Ding, Z., Li, J., Wu, Z., Tam, P. K. H., Wang, Q., et al. (2026) · Advanced Science · doi:10.1002/advs.76054 · Cited by 1
Grice, A. B., Kopell, B. H., Laborc, K. F., Lund, A. N., Chong, R. G., Spadaccia, M. R., Ona, G., Nadkarni, G. N., Crary, J. F., Charney, A. W., et al. (2026) · npj Parkinson s Disease · doi:10.1038/s41531-026-01422-8
Hu, S., Ying, C., Xue, J., Zhao, L., Sun, H., & Cai, Y. (2026) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2026.108416
Apports des techniques d’amplification pour le diagnostic des synucléinopathies
Lamard, E., & Bougard, D. (2026) · médecine/sciences · doi:10.1051/medsci/2026095
Selective Neurodegeneration in Patients with Parkinson’s Disease
Yusupov, F. A., & Abdykadyrov, M. (2026) · Neuroscience and Behavioral Physiology · doi:10.1007/s11055-026-02040-w
Ma, Y., Li, X., Chen, H., & Fan, R. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.1772217
Gaur, P. K., Bisht, P. R., & Gupta, S. L. (2026) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2026.2723464
Pyrgelis, E.-S., Paraskevas, G. P., Constantinides, V. C., Boufidou, F., Stefanis, L., & Kapaki, E. N. (2026) · Diagnostics · doi:10.3390/diagnostics16182889
Yang, X., Zhong, B., Sun, Y., Zhao, B., Zhang, L., Liang, Z., Zhang, Y., Yu, L., & Zhang, L. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c03412
Metadata
- Authors
- Atik, A., Stewart, T., & Zhang, J.
- Affiliations
- University of Washington (US)
- ORCID
- Zhang, Jing
- Venue
- Brain Pathology
- Publisher
- Wiley
- Published
- 2016-04-25
- Volume
- 26
- Issue
- 3
- Pages
- 410-418
- ISSN
- 1015-6305 (ISSN-L)
- 1750-3639
- PMC
- PMC6245641
- OpenAlex
- W2289901196
- Cited by
- 311
- References
- 119
- Citations by year
- 2026: 25 · 2025: 42 · 2024: 36 · 2023: 42 · 2022: 36 · 2021: 42 · 2020: 40 · 2019: 15 · 2018: 13 · 2017: 12 · 2016: 7
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Brain Pathology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (NIH) (U01 NS082137, P30 ES007033-6364, R01 AG033398, R01 ES016873, R01 ES019277, R01 NS057567, and P50 NS062684-6221)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- alpha-synuclein, Parkinson's disease, biomarkers, Lewy bodies, early diagnosis, disease progression monitoring, cerebrospinal fluid, plasma, blood, saliva, combined biomarkers, neurodegeneration
- MeSH terms
- Humans, Parkinson Disease, Biomarkers, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
